Clinical trial
Clarithromycin v Ciprofloxacin Added to Rifampicin + Ethambutol, for Opportunist…
NCT00367913 · British Thoracic Society, Other · Completed
Key facts
| NCT number | NCT00367913 |
|---|---|
| Title | Clarithromycin v Ciprofloxacin Added to Rifampicin + Ethambutol, for Opportunist Mycobacterial Pulmonary Disease |
| Official title | Treatment of Pulmonary Disease Caused by MAIS, M.Xenopi or M.Malmoense: A Comparison of Two Triple Drug Regimens and an Assessment of the Value of Immunotherapy With M.Vaccae |
| Lead sponsor | British Thoracic Society, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Pulmonary Diseases |
| Intervention type | Biological, Drug |
| Interventions | Addition of clarithromycin to rifampicin and ethambutol, Addition of Ciprofloxacin to rifampicin and ethambutol, Vaccination with M.vaccae |
| Enrollment | 400 |
| Start date | Mar 1, 1995 |
| Completion | Sep 1, 2004 |
| First posted | Aug 23, 2006 |
| Last update posted | Aug 23, 2006 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: